Organon & Co.OGNEarnings & Financial Report

NYSE · pharmaceutical industry

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.

NextNov 10, 2026

Revenue

$1.6B

Gross Profit

$857.0M

Operating Profit

$243.0M

Net Profit

$160.0M

Gross Margin

53.5%

Operating Margin

15.2%

Net Margin

10.0%

YoY Growth

1.3%

EPS

$0.61

Financial Flow

Organon & Co. Q3 2025 Financial Summary

Organon & Co. reported revenue of $1.6B for Q3 2025, with a net profit of $160.0M (10.0% margin). Cost of goods sold was $745.0M, operating expenses totaled $614.0M.

Key Financial Metrics

Total Revenue	$1.6B
Net Profit	$160.0M
Gross Margin	53.5%
Operating Margin	15.2%
Report Period	Q3 2025

Organon & Co. Annual Revenue by Year

Organon & Co. annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.4B).

Year	Annual Revenue
2024	$6.4B
2023	$6.3B
2022	$6.2B

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$1.60B	$1.62B	$1.61B	$1.58B	$1.59B	$1.51B	$1.59B	$1.60B
YoY Growth	7.6%	5.5%	-0.1%	4.1%	-0.4%	-6.7%	-0.8%	1.3%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$12.06B	$11.89B	$12.15B	$12.75B	$13.10B	$13.16B	$13.50B	$13.55B
Liabilities	$12.13B	$11.84B	$12.01B	$12.26B	$12.63B	$12.61B	$12.77B	$12.65B
Equity	$-70.0M	$48.0M	$144.0M	$493.0M	$472.0M	$542.0M	$733.0M	$906.0M